Call Text Chat Email Refer a Patient Join a Study

Search

MotherToBaby

Medications and More during pregnancy and breastfeeding

Risperidone

Selected References:

  • Coppola D, et al. 2007. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf; 30(3):247-264. 
  • Cho H, et al. 2025. Antipsychotic use during pregnancy and outcomes in pregnant individuals and newborns. J Affect Disord; 373:495-504. 
  • Damkier P and Videbech P. 2018. The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review. CNS Drugs; 32:351-366. 
  • Eberhard J., et al. 2007. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatrica Scandinavica; 115(4), 268-276. 
  • Ennis ZN and Damkier P. 2014. Pregnancy Exposure to Olanzapine, Quetiapine, Risperidone, Aripiprazole and Risk of Congenital Malformation. A Systemic Review. Basic & Clinical Pharmacology & Toxicology; 116:315-320. 
  • Elstein Y, et al. 2004. Pregnancies in Gaucher disease: a 5 -year study. Am J Obstet Gynecol; 190:435-441. 
  • Habermann F, et al. 2013. Atypical Antipsychotic Drugs and Pregnancy Outcome: A Prospective, Cohort Study. J Clin Psychopharmacol; 33:453-462. 
  • Huybrechts KF, et al. 2016. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry; 73(9): 938-946. 
  • National Library of Medicine. 2026. Drug labeling information (section 8.2). DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a6767972-2d3f-482b-80bd-ac93e28fdd05&type=display#section-8.2 
  • McAllister-Williams RH, et al. 2017.  British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017.  J Psychopharmacol; 31(5): 519-552. 
  • Park Y, et al. 2018. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. Am J Psychiatry; 175(6):564-574. 
  • Petersen I, et al. 2016. Risks and Benefits of Psychotropic Medication in Pregnancy: Cohort Studies based on UK Electronic Primary Care Health Records. Health Technol Assess; 20:1-176 
  • Straub L, et al. 2022. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study. JAMA Intern Med; 182(5):522-533.  
  • Uguz F. 2016. Second-Generation Antipsychotics During the Lactation Period. J Clin Psychopharmacol; 36(3):244-252. 
  • Uguz F. 2019. Adverse events in a breastfed infant exposed to risperidone and haloperidol. Breastfeed Med; 14:683–684. 
  • Vigod SN, et al. 2015. Antipsychotic Drug Use In Pregnancy: High Dimensional, Propensity Matched, Population Based Cohort Study. BMJ; 350:h2298. 
  • Wang E, et al. 2025. Comparative safety of antipsychotic medications and mood stabilizers during pregnancy: A systematic review and network meta-analysis of congenital malformations and prenatal outcomes. CNS Drugs; 39(1):1-22. 

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $1,200,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.